HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peroxisome proliferator-activated receptor-γ ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor.

Abstract
An elevated plasma level of 5-hydroxytryptamine (5-HT) or upregulation of 5-HT receptor signaling or both is implicated in vascular contraction and remodeling in pulmonary arterial hypertension (PAH). Recently, peroxisome proliferator-activated receptor-γ (PPARγ) agonists have been shown to ameliorate PAH. However, their effects on the 5-HT-induced contraction of pulmonary arteries remain unknown. Here, we examined the role of PPARγ in inhibiting 5-HT2B receptor (5-HT2BR) to ameliorate PAH. Pulmonary arteries from PAH rats induced by monocrotaline or chronic hypoxia showed an enhanced vasoconstriction in response to BW723C86, a specific agonist for 5-HT2BR. Expression of 5-HT2BR was also increased in pulmonary arteries from the PAH rats, accompanied by vascular remodeling and right ventricular hypertrophy. Treatment with the PPARγ agonist rosiglitazone in vivo reversed the expression and the vasocontractive effect of 5-HT2BR as well as the thickening of pulmonary arteries. In pulmonary artery smooth muscle cells, 5-HT induced the gene expression of 5-HT2BR, which was inhibited by rosiglitazone, pioglitazone, or adenovirus-mediated overexpression of constitutively activated PPARγ. The pharmacological effect of PPARγ was through the suppression of the 5-HT-induced activator protein-1 activity. These results demonstrated the beneficial effect of PPARγ on 5-HT2BR-mediated vasocontraction, providing a new mechanism for the potential use of PPARγ agonists in PAH.
AuthorsYahan Liu, Xiao Yu Tian, Guangmei Mao, Xi Fang, Man Lung Fung, John Y-J Shyy, Yu Huang, Nanping Wang
JournalHypertension (Dallas, Tex. : 1979) (Hypertension) Vol. 60 Issue 6 Pg. 1471-8 (Dec 2012) ISSN: 1524-4563 [Electronic] United States
PMID23108648 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 1-(5-(2-thenyloxy)-1H-indol-3-yl)propan-2-amine
  • Indoles
  • PPAR gamma
  • Receptor, Serotonin, 5-HT2B
  • Serotonin 5-HT2 Receptor Agonists
  • Thiazolidinediones
  • Thiophenes
  • Transcription Factor AP-1
  • Rosiglitazone
  • Monocrotaline
Topics
  • Animals
  • Familial Primary Pulmonary Hypertension
  • Hypertension, Pulmonary (etiology, metabolism, physiopathology)
  • Hypoxia (complications, metabolism, physiopathology)
  • Indoles (pharmacology)
  • Monocrotaline
  • Muscle, Smooth, Vascular (drug effects, metabolism, physiopathology)
  • Myocytes, Smooth Muscle (drug effects, metabolism)
  • PPAR gamma (agonists, metabolism)
  • Pulmonary Artery (drug effects, metabolism, physiopathology)
  • Receptor, Serotonin, 5-HT2B (metabolism)
  • Rosiglitazone
  • Serotonin 5-HT2 Receptor Agonists (pharmacology)
  • Thiazolidinediones (pharmacology)
  • Thiophenes (pharmacology)
  • Transcription Factor AP-1 (metabolism)
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: